ASCO GU 2021: A Phase II Trial Of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy For Bladder Cancer (RETAIN BLADDER): Interim Analysis

(UroToday.com) For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RC alone. Consolidation with chemoradiotherapy (CRT) is an alternative to RC. Both of these consolidative approaches are associated with short and long-term toxicity and quality of life implications. Thus, there is interest in identifying patients in whom such consolidation could be omitted. In a plenary abstract presentation in the Rapid Abstract Session: Urothelial Carcinoma and Rare Tumors session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Geynisman presented results of a phase II, multi-institutional clinical trial (NCT02710734) to evaluate a risk-adapted approach to the treatment of muscle-invasive bladder cancer (MIBC). 

The authors enrolled patients with cT2-T3N0M0 urothelial carcinoma of the bladder who had ECOG performance status 0-1 and creatinine clearance l≥50 mL/min. These patients underwent NAC with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). Prior to initiating NAC, TURBT specimens were sequenced (Caris Life Sciences) to identify mutations, either pathogenic or variants of unknown significance in ATM, ERCC2, FANCC or RB1. 

Following NAC, patients who had at least one mutation and no clinical evidence of disease by restaging TUR and imaging began a pre-defined active surveillance (AS) regime. The remaining patients who did not meet these criteria underwent bladder-directed therapy: intravesical therapy ( < cT2 post-NAC), CRT or RC. The primary endpoint is metastasis-free survival (MFS) at 2 years, the data for which is not mature, but the authors report key interim results of clinically-meaningful intermediate endpoints.

ASCOGU_ Geynisman_1.png

The authors enrolled 77 patients in the intention-to-treat population over 33 months at four academic centers. The median age of enrolled patients was 70 years (47-83), 74% were male, 92% were Caucasian, 81% had ECOG PS 0 and 79% had cT2 disease. 

90% of enrolled patients completed 3 cycles of NAC, with 17% experiencing grade 3-4 TRAEs and one death during AMVAC. 

As of a data cut-off of September 11, 2020, for the ITT pts, 32 pts have undergone radical cystectomy, 5 underwent CRT and 7 underwent intravesical therapy, at some point during the trial. 

ASCOGU_ Geynisman_2.png

Among 77 enrolled patients, 33 patients (46%) had a mutation of interest and 28 pts (39%) started AS (2 of the 28 pts on AS did not have a mutation but elected to start AS after achieving cT0 post AMVAC). 76% of those with a mutation had no residual disease (cT0) at the time of post-NAC TURBT. With a median follow-up of 14.9 months (range: 3.1-35.3 months), 14 patients who underwent AS had evidence of recurrence (50%). Among 14 recurrences, 2 recurred with locally advanced or metastatic disease and have died, 5 recurred with MIBC with one eventual metastatic recurrence, and 7 recurred with NMIBC. 

Six (14%) patients who did not undergo AS have died. Out of the 40 pts who did not undergo upfront radical cystectomy [AS (N = 28), CRT (N = 5), intravesical tx (N = 7)], 3 patients (7.5%) all of whom underwent AS eventually underwent radical cystectomy. 

Overall, 55% of patients in the ITT cohort and 89% of patients in the AS group had successful bladder preservation. In terms of overall survival, the majority of patients were alive and without metastasis at median follow-up between 18 and 20 months, in both the ITT and AS populations.

ASCOGU_ Geynisman_3.png

In the AS cohort, mutations were seen in RB1 (50%), ATM (42%), ERCC2 (31%), FANCC (4%) with differences in recurrence rates based on mutation status: ERCC2 (25% recurrence) vs RB1 (62% recurrence).

The authors conclude that, based on these interim results, a risk adapted approach allows active surveillance of a subset of patients with MIBC who achieve pathologic complete response from NAC, thus sparing the toxicity of consolidative therapy.


Presented by: Daniel M. Geynisman, MD, Associate Professor, Department of Hematology/Oncology, NCCN, Testicular Cancer Panel Member, Fox Chase Cancer Center

Written by: Christopher J.D. Wallis, Urologic Oncology Fellow, Vanderbilt University Medical Center, Contact: @WallisCJD on Twitter during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (#GU21), February 11th-February 13th, 2021
email news signup